Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
Pfizer claims FDA okay for rare heart disease drug tafamidisThe FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first Share XPfizer claims FDA okay for rare heart disease drug tafamidishttps://pharmaphorum.com/news/pfizer-claims-fda-okay-for-rare-heart-disease-drug-tafamidis/
Pfizer set for July FDA verdict on rare heart disease drugPfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after Share XPfizer set for July FDA verdict on rare heart disease drughttps://pharmaphorum.com/news/pfizer-set-for-july-fda-verdict-on-rare-heart-disease-drug/
Pfizer drug reduces mortality in patients with fatal heart diseasePfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase Share XPfizer drug reduces mortality in patients with fatal heart diseasehttps://pharmaphorum.com/news/tafamidis-reduces-mortality/
